Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q4 2025 (← Previous) (Next →)

Filing Date: Feb 12, 2026

Total Value: $151M (100.0% shares, 0.0% debt)

Holdings (7)

GLUE Monte Rosa Therapeutics, Inc. 45.5%

Value $68.72M Shares 4,382,687 Est. Cost $7.50 Unrealized +79.6%

LENZ Lenz Therapeutics, Inc. 28.1%

Value $42.51M Shares 2,656,888 Est. Cost $36.77 Unrealized -20.7%

JBIO Jade Biosciences, Inc. 15.6%

Value $23.54M Shares 1,525,820 Est. Cost $33.31 Unrealized -64.8%

CRSP CRISPR Therapeutics AG 5.2%

Value $7.805M Shares 148,831 Est. Cost $40.26 Unrealized +48.7%

CTNM Contineum Therapeutics, Inc. 4.1%

Value $6.202M Shares 542,628 Est. Cost $16.10 Unrealized -29.2%

SKYE Skye Bioscience, Inc. 1.0%

Value $1.505M Shares 2,007,704 Est. Cost $7.75 Unrealized -81.2%

— Tempest Therapeutics, Inc. 0.5%

Value $774K Shares 269,772 Est. Cost $6.80 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
GLUE	Monte Rosa Therapeutics, Inc.	4,382,687	$68.72M	45.5%	$7.50	+79.6%	Common Stock	61225M102
LENZ	Lenz Therapeutics, Inc.	2,656,888	$42.51M	28.1%	$36.77	-20.7%	Common Stock	52635N103
JBIO	Jade Biosciences, Inc.	1,525,820	$23.54M	15.6%	$33.31	-64.8%	Common Stock	008064206
CRSP	CRISPR Therapeutics AG	148,831	$7.805M	5.2%	$40.26	+48.7%	Common Shares	H17182108
CTNM	Contineum Therapeutics, Inc.	542,628	$6.202M	4.1%	$16.10	-29.2%	Common Stock	21217B100
SKYE	Skye Bioscience, Inc.	2,007,704	$1.505M	1.0%	$7.75	-81.2%	Common Stock	83086J200
—	Tempest Therapeutics, Inc.	269,772	$774K	0.5%	$6.80	—	Common Stock	87978U108